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h.schock@dkfz.deAbstractWell-established associations between reproductive characteristics and epithelial ovarian
cancer (EOC) support an involvement of sex steroid hormones in the etiology of EOC. Limited
previous studies have evaluated circulating androgens and the risk of EOC, and estrogens
and progesterone have been investigated in only one of the previous studies. Furthermore,
there is little data on potential heterogeneity in the association between circulating
hormones and EOC by histological subgroup. Therefore, we conducted a nested case–control
study within the Finnish Maternity Cohort and the Northern Sweden Maternity Cohort to
investigate the associations between circulating pre-diagnostic sex steroid concentrations
and the histological subtypes of EOC. We identified 1052 EOC cases among cohort members
diagnosed after recruitment (1975–2008) and before March 2011. Up to three controls
were individually matched to each case (nZ2694). Testosterone, androstenedione,
17-hydroxyprogesterone (17-OHP), progesterone, estradiol (E2), and sex hormone-binding
globulin levels were measured in serum samples collected during the last pregnancy before
EOC diagnosis. We used conditional logistic regression to estimate odds ratios (ORs) and
95% CIs. Associations between hormones and EOC differed with respect to tumor histology
and invasiveness. Sex steroid concentrations were not associated with invasive serous
tumors; however, doubling of testosterone and 17-OHP concentration was associated with
approximately 40% increased risk of borderline serous tumors. A doubling of androgen
concentrations was associated with a 50% increased risk of mucinous tumors. The risk of
endometrioid tumors increased with higher E2 concentrations (OR: 1.89 (1.20–2.98)).
This large prospective study in pregnant women supports a role of sex steroid hormones
in the etiology of EOC arising in the ovaries.Key Words
" prospective study
" case–control study
" pregnancy
" sex steroids
" ovarian neoplasmsEndocrine-Related Cancer
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Research H Schock et al. Sex steroid hormones and EOC 21 :6 832IntroductionWorldwide, more than 200 000 women are diagnosed
with epithelial ovarian cancer (EOC) each year. It is the
seventh most common cancer in women and the leading
cause of gynecological cancer death among women with
an overall 5-year survival rate of approximately 40% only
in developed countries (Ferlay et al. 2014). EOC can be
subdivided into invasive and borderline diseases; approxi-
mately 15% of EOC are borderline tumors with similar
epidemiological risk factors to invasive tumors, but
occurring at a younger age, presenting at an earlier stage,
and with a more favorable prognosis (Trope et al. 2012).
Furthermore, EOC includes different histological
subtypes, with the most common being serous (75%),
endometrioid (10%), clear cell (10%), and mucinous (3%)
(Prat 2012). Growing evidence indicates that EOC
subgroups represent clinically, morphologically, and
molecularly distinct diseases (Prat 2012).
EOC may develop from inclusion cysts by metaplasia
of ovarian surface epithelium or implantation of other
epithelia (e.g. tubal tissue; Auersperg et al. 2001, Kurman &
Shih 2010). The pathogenic mechanisms involved in the
development of ovarian cancer are poorly understood. The
prevailing etiological hypotheses implicate long periods
of ovulatory cycles (Fathalla 1971), retrograde menstrual
flow (Cramer & Xu 1995), and endogenous, as well as
exogenous, hormonal exposure (Risch 1998). Sex steroid
hormones (androgens, progesterone, and estradiol (E2))
are likely to be involved in the etiology of EOC, as there
are well-established associations between reproductive
characteristics affecting sex steroid concentrations and
EOC. Examples include the protective effect of pregnancy
and the use of oral contraceptives (OCs), and the increased
risk associated with the current use of hormone replace-
ment therapy (Morch et al. 2009, Tsilidis et al. 2011).
To date, studies directly relating pre-diagnostic
endogenous hormone concentrations to the risk of EOC
are confined to androgens and results are inconclusive
(Helzlsouer et al. 1995, Lukanova et al. 2003, Rinaldi et al.
2007, Tworoger et al. 2008, Ose et al. 2014). Only one small
study related progesterone and E2 to the risk of EOC
(Helzlsouer et al. 1995). This is most probably because
concentrations of progesterone and E2 show large intra-
individual variations during the menstrual cycle among
premenopausal women, making measurement difficult,
and concentrations in postmenopausal women are low
(Rannevik et al. 1995, Speroff & Marc 2005).
Given the sparse data on the relationship between sex
steroid hormones and EOC, and the establishedhttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britainassociation between parity and EOC, we investigated
early pregnancy sex steroid hormones and the subsequent
ovarian cancer risk in a case–control study nested in two
prospective maternity cohorts. Furthermore, we present
the first data, to our knowledge, on early pregnancy
hormones and the risk of EOC on the basis of histological
subtype and invasiveness. Androgens in early pregnancy
are similar to preconception concentrations; therefore,
our study characterizes premenopausal circulating andro-
gen concentrations with a risk of EOC. On the other hand,
progesterone and E2 levels are elevated in early pregnancy
and their concentrations increase further during pregnancy;
thus, we are able to explore whether these hormones
contribute to the protective effect conferred by pregnancy.Materials and methods
Study population
A case–control study was nested within the Finnish
Maternity Cohort (FMC) and the Northern Sweden
Maternity Cohort (NSMC). These two bio-repositories
store serum samples collected during the late weeks of
the first, or early weeks of the second, trimester at K25
and K20 8C respectively. The FMC was established in
1983 and includes approximately two million specimens
from almost 99% of pregnancies in the country (http://
www.thl.fi/en/web/thlfi-en/research-and-expertwork/
projects-and-programmes/projects/28232, accessed May
2014). The NSMC was established in 1975 and contains
almost 120 000 samples from pregnancies in the three
northernmost counties of Sweden (Pukkala 2011).
Study subjects were selected among members from the
two cohorts with: i) no history of twin or multiple
pregnancies; ii) a blood sample obtained during the first
trimester of a pregnancy leading to childbirth; and iii) no
history of invasive cancer (except for non-melanoma skin
cancer) and/or borderline ovarian cancer before blood
donation.
Identification of cases Cases diagnosed with invasive
or borderline EOC after blood donation were identified
through linkages with the Finnish Cancer Registry
(founded in 1952) and the Swedish Cancer Registry
(founded in 1958). Reporting of newly diagnosed cases
is mandatory in both nationwide cancer registries, leading
to very high (O95%) completeness for solid tumors
(Teppo et al. 1994, Barlow et al. 2009). We identified
1105 incident EOC cases among FMC participants andPublished by Bioscientifica Ltd.
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were diagnosed before December 2009 and March 2011
respectively. The serum sample from the last singleton
pregnancy (or the most recent available for 68 cases)
resulting in delivery of a neonate before diagnosis was
selected for the study.
Selection of controls Selection of controls was
carried out in two steps. First, up to 12 potentially eligible
controls were selected for each case through linkages with
the national population registries. Controls matching the
case on study cohort, age at sampling (G6 months), date
of sampling (G3 months), parity at sampling (1, 2, andO2
children), and parity at diagnosis (1, 2, and O2 children)
were selected using incidence density sampling. In a
second step, up to three controls were selected at random.
Cases with insufficient serum volume for laboratory
measurements (FMC: nZ157 and NSMC: nZ31) and cases
for whom no eligible controls could be identified (FMC:
nZ5 and NSMC: nZ6) were excluded. Therefore, a total
of 1052 EOC cases (FMC: nZ943 and NSMC: nZ109) and
2694 controls (FMC: nZ2383 and NSMC: nZ311) were
included in the study.
Morphology codes were provided by the Finnish and
Swedish cancer registries and recoded according to the
World Health Organization guidelines (Lee et al. 2003) to
histological subgroups of EOC as serous (nZ477, 45%),
mucinous (nZ356, 34%), endometrioid (nZ102, 10%),
clear cell (nZ26, 3%), and not otherwise specified (NOS)
(nZ66, 6%) tumors. Data on histology were not available
for 25 cases (2%), and, thus, they were included only in
overall analyses and analyses of tumor invasiveness, as
were tumors diagnosed as NOS. Data on the stage of EOC
at diagnosis were not available for cases from the NSMC,
but were available for 87% of cases from the FMC. For cases
from the FMC, stage I (nZ482, 58%) was classified as
localized, whereas stages II (nZ6), III (nZ306), and IV
(nZ30) were classified as advanced EOC (nZ342, 42%).
Characteristics related to pregnancy (e.g. pregnancy
length, smoking during pregnancy, maternal age at first
birth, and number of incomplete pregnancies) and to the
newborn (e.g. gender, and birth weight and length) were
obtained through linkages from the country-specific birth
registries. For 2200 members of the FMC (nZ629
case–control sets, 60%) information on malignant cancers
diagnosed among first-degree relatives was obtained
through linkages with the Finnish population and Cancer
registries.
This study was approved by the ethical committees
of the National Institute for Health and Welfare, Finland,http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great BritainUniversity of Umea˚, Sweden, and German Cancer
Research Center, Germany.Laboratory analyses
All hormonal analyses were performed at the Clinical
Chemistry Laboratory of Umea˚ University Hospital,
Umea˚, Sweden. Serum specimens of individually matched
case and control subjects were always included in the
same laboratory batch. The technicians performing the
assays were blinded to the case, control, or quality control
status of the specimens. In addition to routine laboratory
quality controls, two pools of serum from each of the
cohorts were created at the beginning of the study and
three aliquots, undistinguishable from the test samples,
were inserted in each laboratory run.
Concentrations of androgens (testosterone and
androstenedione), 17-hydroxyprogesterone (17-OHP),
progesterone, and E2 were quantified by HPLC tandem
mass spectrometry on an Applied Biosystems API4000
triple-stage quadrupole mass spectrometer. Inter- and
intra-run coefficient of variation (CV) values based
on the blinded pooled quality controls were !10 and
!11%, respectively, for samples from the FMC and !11
and !9%, respectively, for samples from the NSMC for
all sex steroids.
Sex hormone-binding globulin (SHBG) was quantified
by solid-phase competitive chemiluminescence assays on
an Immulite 2000 Siemens analyzer. Inter- and intra-run
CV values based on the blinded pool quality controls were
!10% in both cohorts.Statistical analysis
All hormone values were log2-transformed to normalize
their distributions and to allow for the estimation of the
risk with a doubling of hormone concentration. Concen-
trations of progesterone, 17-OHP, E2, and SHBG varied
linearly with the gestational age (rZ0.49,K0.26, 0.69, and
0.57, respectively; P!0.0001); thus, analyses including
these hormones were limited to women with information
on gestational age (nZ765 case–control sets, 73%) and
gestational age was included as a covariate in the statistical
models. Pearson’s partial correlation coefficients were
used to assess correlations between individual hormone
concentrations in control samples.
We used conditional logistic regression to assess
differences between cases and controls and to calculate
odds ratios (ORs) and the corresponding 95% CIs. For each
of the hormones, ORs were calculated for tertiles ofPublished by Bioscientifica Ltd.
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quency distribution in controls. Likelihood ratio tests were
used to assess linear trends across categories based on the
median hormone values for the tertiles. In addition, ORs
were calculated for a unit change of log2-transformed
hormones.
The effect of potential confounders (maternal age at
first birth, smoking during index pregnancy, family history
of breast and/or ovarian cancers, child’s sex, and birth
length and weight) was evaluated. Missing values were
assigned to a ‘missing’ category for categorical covariates,
whereas, for continuous variables, missing values were
assigned the individual cohort (NSMC or FMC) median
value for that variable. Analyses that excluded subjects
with missing values for any of these covariates were similar
to those with values imputed as described. Among the
available covariates, none changed point estimates by
O10%. We repeated the analyses for each of the hormones
mutually adjusting for the other hormones.
Stratified analyses were performed by histology, ages
at sampling and diagnosis (histology-specific; below/
above median), and the time between blood donation
and diagnosis (i.e., ‘lag-time’; below/above median).
We also stratified by the stage (localized vs advanced
disease), the number of children by diagnosis date of
the matched case (1 vs O1), and the age at diagnosis (age
of !51 vs R51 years). The cut-off for age at diagnosis
was chosen as the average age at menopause is 51 years
in Sweden and Finland (Thomas et al. 2001). Tests of
heterogeneity between the ORs in different subgroups
were based on c2 statistics, calculated as the deviations
of logistic regression coefficients observed in each of the
subgroups, relative to the overall regression coefficient
(Whitehead & Whitehead 1991).
We conducted sensitivity analyses limited to women
diagnosed at least 2 or 3 years after blood donation to
assess whether the study results were influenced by the
presence of undiagnosed, but hormonally active tumors.
Additionally, we performed analyses limited to women
with a full-term pregnancy or, for androgen analyses,
with information on gestational age at blood sampling.
Results adjusted for gestational age were similar to those
for hormone concentrations for each study subject
computed as the difference (residual) between the assay
value and the estimated cohort-specific mean value
determined for the day of gestation when the sample
was drawn using local linear regression (Cleveland &
Loader 1996; data not shown).
All statistical tests were two-sided with a significance
level of 0.05. Statistical analyses were performed usinghttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britainthe Statistical Analyses System (SAS), version 9.2 Software
(SAS Institute, Inc., Cary, NC, USA). The figure was
prepared using the R software (package ‘rmeta’, function
‘forestplot) version 2.15.2 (R Core Team 2014).Results
Key characteristics of the study subjects and their new-
borns by study cohort are presented in Table 1. The
majority of the 1052 cases (nZ943, FMC and nZ109,
NSMC) were diagnosed with invasive EOC (nZ642, 61%).
Out of them, 283 (44%) were serous, 150 (23%) mucinous,
102 (16%) endometrioid, and 26 (4%) clear cell. Among
the borderline tumors (nZ410, 39%), 194 (47%) were
serous and 206 (50%) mucinous. The distribution by
histological subtype and invasiveness was consistent
between the two cohorts. Invasive tumors were predomi-
nantly diagnosed as advanced disease (69%), whereas
almost all borderline tumors were diagnosed as localized
disease (97%). Median age at EOC diagnosis was 43.9 years
and on average 12.2 years elapsed between blood donation
and diagnosis among all cases.
In the FMC, maternal and child characteristics were
similar for both cases and controls except for median age
at first birth (26.0 vs 26.9; P!0.0001), smoking during
pregnancy (22 vs 14%; P!0.0001), and family history of
breast and/or ovarian cancer (8 vs 5%; PZ0.008). In the
NSMC, only smoking during pregnancy was markedly
different between cases and controls (38 vs 28%; PZ0.06).
Cases with mucinous tumors (borderline and invasive)
had the shortest lag-time between blood collection and
cancer diagnosis (10.2 years) and the youngest median age
at diagnosis (40.1 and 40.9 years respectively), whereas
cases diagnosed with endometrioid or clear cell tumors
had the longest lag-time (16.3 and 17 years respectively)
and were the oldest at diagnosis (48.1 years) (Table 2).
Cases with borderline tumors were younger at first
birth, those with borderline and invasive mucinous and
invasive serous tumors were more likely to smoke, and
those with invasive serous tumors were more likely to have
a family history of breast and/or ovarian cancer relative
to their matched controls (Table 2).
Case subjects from both cohorts had significantly
higher geometric means of testosterone (FMC: 0.87 vs
0.79 ng/ml; P!0.0001 and NSMC: 0.83 vs 0.72 ng/ml;
PZ0.004) and androstenedione (FMC: 1.91 vs 1.73 ng/ml;
P!0.0001 and NSMC: 1.98 vs 1.71; PZ0.007) relative to
control subjects. In the FMC, 17-OHP levels were also
higher in cases compared with controls (2.37 vs
2.24 ng/ml; PZ0.006).Published by Bioscientifica Ltd.
Table 1 Distribution of characteristics of EOC cases and their matched controls, median (min and max) or n (%) from the Finnish
Maternity Cohort (1983–2009) and the Northern Sweden Maternity Cohort (1975–2011)a
Characteristics
Missing
(%)b
Finnish Maternity Cohort
P
Missing
(%)b
Northern Sweden Maternity
Cohort
PCases (943) Controls (2383) Cases (109) Controls (311)
Age at blood donation
(years)
– 31.8 (16.4–45.7) 31.7 (15.7–45.5) – – 29.0 (17.3–41.7) 28.8 (17.4–42.8) –
Parity at index pregnancy – – – –
1 child 231 (24%) 597 (25%) 59 (54%) 170 (55%)
2 children 386 (41%) 981 (41%) 27 (25%) 76 (24%)
O2 children 326 (35%) 805 (34%) 23 (21%) 65 (21%)
Gestational age (days) 25 75 (39–142) 73 (39–142) 0.50 – 75 (38–148) 73 (38–148) 0.16
Age at first birth (years)c – 26.0 (14.8–46.2) 26.9 (14.6–45.9) !0.0001 15 24.9 (16.1–40.8) 24.8 (16.8–40.0) 0.56
Pregnancy length (weeks)c 25 0.38 – 0.12
!37 35 (5%) 84 (5%) 1 (1%) 13 (4%)
R37 618 (95%) 1768 (95%) 108 (99%) 298 (96%)
Child weight (g)c 25 3620 (460–5100) 3610 (580–5260) 0.50 – 3460 (1480–4500) 3500 (900–5920) 0.78
Child length (cm)c 25 51 (29–57) 50 (25–56) 0.95 – 50 (41–55) 50 (33–56) 0.42
Child gender 0.1 0.46 – 0.18
Male 481 (51%) 1255 (53%) 48 (44%) 160 (51%)
Female 461 (49%) 1126 (47%) 61 (56%) 151 (49%)
Smoking during
pregnancyc
27 138 (22%) 245 (14%) !0.0001 2 41 (38%) 85 (28%) 0.06
Family history of breast
and/or ovarian cancer
34 51 (8%) 81 (5%) 0.008 100 – – –
Age at diagnosis (years) – 43.3 (19.0–66.0) – 47.8 (20.2–68.0)
Years between blood
draw and diagnosis
– 11.5 (0.1–25.6) – 19.5 (1.3–31.7)
Cancer type – 23
Borderline 367 (39%) 43 (39%)
Serous 174 (47%) 20 (51%)
Mucinous 189 (52%) 17 (44%)
NOS 4 (1%) 2 (5%)
Invasive 576 (61%) 66 (61%)
Serous 263 (46%) 20 (44%)
Mucinous 143 (25%) 7 (16%)
Endometrioid 92 (16%) 10 (22%)
Clear Cell 23 (4%) 3 (7%)
NOS 55 (9%) 5 (11%)
Disease spreadd 13 100 –
Localized (stage I) 482 (58%)
Advanced (stage II–IV) 342 (42%)
Hormonese,f
Testosterone (ng/ml) 0.5 0.87 (0.84–0.90) 0.79 (0.78–0.81) !0.0001 1 0.83 (0.76–0.90) 0.72 (0.68–0.75) 0.004
Androstenedione (ng/ml) 0.5 1.91 (1.85–1.97) 1.73 (1.71–1.77) !0.0001 1 1.98 (1.81–2.16) 1.71 (1.63–1.81) 0.007
17–OHP (ng/ml) 25 2.37 (2.29–2.46) 2.24 (2.19–2.29) 0.006 1 2.21 (2.02–2.42) 2.03 (1.93–2.14) 0.16
Progesterone (ng/ml) 25 24.9 (24.3–25.5) 24.4 (24.1–24.8) 0.34 1 21.4 (19.9–23.0) 21.4 (20.5–22.3) 0.97
Estradiol (ng/ml) 25 1.97 (1.89–2.05) 1.89 (1.85–1.94) 0.09 1 1.96 (1.75–2.19) 1.84 (1.72–1.96) 0.35
SHBG (nmol/l) 27 211 (205–218) 205 (201–209) 0.11 5 122 (107–140) 131 (121–142) 0.33
NOS, not otherwise specified; 17-OHP, 17-hydroxyprogesterone; SHBG, sex hormone-binding globulin.
aConditional logistic regression models were used to compare differences between cases and controls.
bPercentage of missing values, – indicates no missing values.
cData from the Finnish Birth Registry are available since 1987.
dPercentage of missing values among cases.
eGeometric means and 10th–90th percentile of hormone concentrations (adjusted for study cohort and, except for androgens and gestational age).
fConversion from ng/ml to nmol/l (SI units): testosterone!3.467, androstenedione!3.49, 17-OHP!3.025, progesterone!3.18, and estradiol!3.671.
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Research H Schock et al. Sex steroid hormones and EOC 21 :6 835Associations between early pregnancy hormones and
EOC differed by tumor histology and, for the serous
subtype, also by tumor invasiveness (Table 3 and Fig. 1).
We did not observe any association between the evaluated
hormones and the risk of invasive serous or clear cellhttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britaintumors in our study population. High progesterone and
SHBG were not associated with the risk of EOC overall
or with the histological subgroups.
High testosterone was associated with a significantly
increased risk of borderline serous tumors (3rd vsPublished by Bioscientifica Ltd.
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Table 3 ORs (95% CI) by tumor invasiveness and histology across tertiles of circulating hormone concentrations from the Finnish
Maternity Cohort (1983–2009) and the Northern Sweden Maternity Cohort (1975–2011)a
Cases/controls
Tertiles
Ptrend Phet
bT1 T2 T3
Testosterone
All women 1047/2673 Ref. 1.27 (1.06–1.53) 1.56 (1.30–1.87) !0.0001
Invasive 640/1609 Ref. 1.18 (0.93–1.49) 1.37 (1.08–1.72) 0.008 0.08
Borderline 407/1064 Ref. 1.45 (1.07–1.96) 1.94 (1.43–2.63) !0.0001
Invasive serous 282/713 Ref. 1.11 (0.78–1.57) 0.99 (0.70–1.41) 0.97 0.03
Borderline serous 193/499 Ref. 1.62 (1.06–2.48) 1.87 (1.18–2.96) 0.008
Invasive mucinous 150/388 Ref. 1.21 (0.74–1.98) 1.79 (1.10–2.90) 0.02 0.76
Borderline mucinous 204/537 Ref. 1.36 (0.88–2.10) 1.97 (1.30–2.99) 0.001
Endometrioid 101/235 Ref. 1.41 (0.74–2.68) 1.83 (0.97–3.45) 0.06
Clear cell 26/65 Ref. 0.52 (0.16–1.66) 0.62 (0.21–1.84) 0.36
Androstenedione
All women 1049/2677 Ref. 1.03 (0.85–1.24) 1.50 (1.24–1.80) !0.0001
Invasive 640/1609 Ref. 0.91 (0.71–1.16) 1.36 (1.08–1.72) 0.004 0.21
Borderline 409/1068 Ref. 1.25 (0.91–1.70) 1.74 (1.29–2.35) 0.0003
Invasive serous 282/714 Ref. 0.98 (0.69–1.41) 1.25 (0.88–1.77) 0.19 0.72
Borderline serous 193/499 Ref. 1.37 (0.87–2.16) 1.38 (0.88–2.18) 0.18
Invasive mucinous 150/387 Ref. 0.98 (0.58–1.64) 1.78 (1.09–2.92) 0.01 0.73
Borderline mucinous 206/541 Ref. 1.14 (0.74–1.77) 2.00 (1.32–3.02) 0.001
Endometrioid 101/235 Ref. 0.71 (0.37–1.38) 0.98 (0.54–1.79) 0.85
Clear cell 26/65 Ref. 0.90 (0.27–3.06) 1.00 (0.33–3.07) 0.99
17-OHP
All women 762/2138 Ref. 1.05 (0.85–1.30) 1.26 (1.01–1.56) 0.04
Invasive 451/1251 Ref. 0.90 (0.68–1.18) 1.10 (0.83–1.46) 0.48 0.14
Borderline 311/887 Ref. 1.35 (0.96–1.88) 1.53 (1.09–2.15) 0.02
Invasive serous 198/555 Ref. 0.96 (0.63–1.44) 1.09 (0.72–1.67) 0.69 0.11
Borderline serous 147/418 Ref. 1.56 (0.96–2.55) 1.85 (1.14–2.99) 0.02
Invasive mucinous 114/321 Ref. 0.68 (0.38–1.21) 1.11 (0.65–1.91) 0.56 0.71
Borderline mucinous 156/445 Ref. 1.25 (0.78–2.00) 1.28 (0.78–2.08) 0.35
Endometrioid 60/159 Ref. 1.12 (0.53–2.37) 0.84 (0.38–1.85) 0.69
Clear cell 17/46 Ref. 0.61 (0.15–2.52) 0.52 (0.10–2.76) 0.42
Progesterone
All women 761/2136 Ref. 0.88 (0.71–1.08) 0.96 (0.76–1.21) 0.67
Invasive 451/1252 Ref. 0.90 (0.68–1.19) 0.99 (0.73–1.35) 0.95 0.71
Borderline 310/884 Ref. 0.85 (0.62–1.18) 0.91 (0.63–1.31) 0.56
Invasive serous 198/555 Ref. 0.98 (0.64–1.48) 1.03 (0.65–1.63) 0.93 0.96
Borderline serous 146/415 Ref. 0.86 (0.53–1.41) 1.05 (0.61–1.82) 0.92
Invasive mucinous 114/322 Ref. 1.04 (0.59–1.85) 1.11 (0.60–2.06) 0.73 0.47
Borderline mucinous 156/445 Ref. 0.75 (0.48–1.18) 0.83 (0.50–1.37) 0.42
Endometrioid 60/159 Ref. 0.61 (0.28–1.32) 0.81 (0.34–1.95) 0.59
Clear cell 17/46 Ref. 0.24 (0.04–1.53) 0.47 (0.10–2.23) 0.43
Estradiol
All women 761/2136 Ref. 1.01 (0.81–1.26) 1.24 (0.94–1.62) 0.11
Invasive 451/1252 Ref. 1.00 (0.75–1.33) 1.26 (0.88–1.79) 0.20 0.88
Borderline 310/884 Ref. 1.03 (0.73–1.46) 1.20 (0.79–1.84) 0.36
Invasive serous 198/555 Ref. 0.79 (0.51–1.21) 0.98 (0.57–1.69) 0.89 0.78
Borderline serous 146/415 Ref. 0.82 (0.50–1.35) 0.87 (0.46–1.64) 0.64
Invasive mucinous 114/322 Ref. 1.06 (0.59–1.89) 1.54 (0.77–3.07) 0.21 0.74
Borderline mucinous 156/445 Ref. 1.42 (0.85–2.35) 1.80 (1.00–3.22) 0.04
Endometrioid 60/159 Ref. 1.41 (0.59–3.41) 2.76 (1.04–7.33) 0.03
Clear cell 17/46 Ref. 1.93 (0.46–8.08) 1.58 (0.26–9.64) 0.53
SHBG
All women 735/2088 Ref. 1.01 (0.81–1.26) 1.14 (0.89–1.46) 0.40
Invasive 429/1209 Ref. 1.00 (0.75–1.34) 1.11 (0.80–1.53) 0.64 0.79
Borderline 306/879 Ref. 1.03 (0.73–1.45) 1.19 (0.80–1.77) 0.45
Invasive serous 185/528 Ref. 1.25 (0.81–1.92) 1.02 (0.63–1.67) 0.83 0.90
Borderline serous 143/413 Ref. 0.94 (0.58–1.54) 1.08 (0.59–1.96) 0.85
Invasive mucinous 113/319 Ref. 0.73 (0.40–1.31) 1.37 (0.72–2.62) 0.56 0.99
Borderline mucinous 155/443 Ref. 1.20 (0.73–1.98) 1.38 (0.79–2.43) 0.27
Endometrioid 55/150 Ref. 0.88 (0.37–2.10) 1.29 (0.51–3.26) 0.63
Clear cell 15/43 Ref. 0.91 (0.20–4.24) 1.25 (0.24–6.53) 0.86
17-OHP, 17-hydroxyprogesterone; OR, odds ratio; SHBG, sex hormone-binding globulin.
aAdjusted for gestational age (except for testosterone and androstenedione).
bHeterogeneity was tested between invasive and borderline tumors.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research H Schock et al. Sex steroid hormones and EOC 21 :6 837
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britain
Published by Bioscientifica Ltd.
All women (n=1047)
Te
st
os
te
ro
ne
A
nd
ro
ste
ne
di
on
e
17
-O
H
P
Pr
og
es
te
ro
ne
Es
tra
di
ol
SH
BG
Invasive (n=640)
Borderline (n=407)
Invasive serous (n=282)
Borderline serous (n=193)
Invasive mucinous (n=150)
Borderline mucinous (n=204)
Endometrioid (n=101)
Clear cell (n=26)
All women (n=1049)
Invasive (n=640)
Borderline (n=409)
Invasive serous (n=282)
Borderline serous (n=193)
Invasive mucinous (n=150)
Borderline mucinous (n=206)
Endometrioid (n=101)
Clear cell (n=26)
All women (n=762)
Invasive (n=451)
Borderline (n=311)
Invasive serous (n=198)
Borderline serous (n=147)
Invasive mucinous (n=114)
Borderline mucinous (n=156)
Endometrioid (n=60)
Clear cell (n=17)
All women (n=761)
Invasive (n=451)
Borderline (n=311)
Invasive serous (n=198)
Borderline serous (n=146)
Invasive mucinous (n=114)
Borderline mucinous (n=156)
Endometrioid (n=60)
Clear cell (n=17)
All women (n=761)
Invasive (n=451)
Borderline (n=310)
Invasive serous (n=198)
Borderline serous (n=146)
Invasive mucinous (n=114)
Borderline mucinous (n=156)
Endometrioid (n=60)
Clear cell (n=17)
All women (n=735)
Invasive (n=429)
Borderline (n=306)
Invasive serous (n=185)
Borderline serous (n=143)
Invasive mucinous (n=113)
Borderline mucinous (n=155)
Endometrioid (n=55)
Clear cell (n=15)
1.32 (1.19–1.47)
1.24 (1.08–1.42)
1.47 (1.23–1.76)
1.02 (0.82–1.26)
1.41 (1.08–1.86)
1.33 (1.01–1.74)
1.50 (1.18–1.90)
1.39 (0.96–1.99)
1.12 (0.61–2.08)
1.35 (1.21–1.51)
1.31 (1.13–1.51)
1.43 (1.20–1.72)
1.18 (0.95–1.46)
1.26 (0.95–1.67)
1.50 (1.12–2.01)
1.56 (1.22–1.99)
1.02 (0.71–1.48)
1.46 (0.74–2.85)
1.23 (1.08–1.40)
1.21 (1.02–1.43)
1.26 (1.03–1.55)
1.16 (0.90–1.51)
1.46 (1.08–1.97)
1.30 (0.93–1.82)
1.13 (0.84–1.51)
0.90 (0.54–1.49)
0.66 (0.26–1.65)
1.08 (0.90–1.29)
1.12 (0.89–1.42)
1.02 (0.77–1.34)
1.18 (0.83–1.66)
1.38 (0.85–2.26)
1.07 (0.71–1.62)
1.04 (0.70–1.53)
0.93 (0.48–1.82)
0.63 (0.20–1.94)
1.11 (0.99–1.25)
1.11 (0.95–1.28)
1.12 (0.94–1.33)
0.93 (0.74–1.17)
1.06 (0.80–1.40)
1.22 (0.91–1.63)
1.24 (0.98–1.57)
1.89 (1.20–2.98)
1.12 (0.56–2.26)
1.05 (0.92–1.21)
1.04 (0.87–1.24)
1.06 (0.86–1.31)
0.98 (0.74–1.29)
0.98 (0.73–1.32)
1.09 (0.77–1.56)
1.20 (0.88–1.63)
1.10 (0.64–1.89)
1.11 (0.39–3.16)
0.5 1.0 1.5 2.0 2.5
Figure 1
Risk (OR (95% CI)) by tumor histology of epithelial ovarian cancer per unit
change in log2 concentrations of circulating testosterone, androstene-
dione, 17-hydroxyprogesterone (17-OHP), progesterone, estradiol, and sex
hormone-binding globulin (SHBG), adjusted for gestational age (except for
androstenedione and testosterone). The number of case–control sets is
indicated in parentheses for each subgroup.
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Research H Schock et al. Sex steroid hormones and EOC 21 :6 8391st tertile: 1.87 (1.18–2.96); PtrendZ0.008) and an
almost twofold increased risk of invasive and borderline
mucinous tumors (3rd vs 1st tertile: 1.79 (1.10–2.90);
PtrendZ0.02 and 1.97 (1.30–2.99); PtrendZ0.001 respect-
ively). High androstenedione concentrations were associ-
ated with an increased risk of invasive and borderline
mucinous tumors (3rd vs 1st tertile: 1.78 (1.09–2.92);
PtrendZ0.01 and 2.00 (1.32–3.02); PtrendZ0.001 respect-
ively). High concentrations of 17-OHP were associated with
an increased risk of borderline serous tumors (3rd vs 1st
tertile: 1.85 (1.14–2.99); PtrendZ0.02). A significantly
increased risk was observed for high E2 concentrations for
endometrioid tumors (3rd vs 1st tertile: 2.76 (1.04–7.33);
PtrendZ0.03), as well as for borderline mucinous tumors
(3rd vs 1st tertile: 1.80 (1.00–3.22); PtrendZ0.04).
We then assessed the effects of mutually adjusting
for the evaluated hormones (Supplementary Table 1, see
section on supplementary data given at the end of this
article). Including androgens or 17-OHP in models
evaluating the association of a doubling of progesterone
or E2 concentrations (and vice versa) with the risk of
EOC did not change the direction or the significance of
the observed associations. After adjustment for andro-
stenedione, the effect of a doubling of testosterone
concentrations on invasive and borderline mucinous
tumors was strongly attenuated and no longer significant
(0.77 (0.43–1.36); PZ0.36 and 1.12 (0.73–1.71); PZ0.60),
whereas the association with endometrioid tumors
was strengthened (3.45 (1.62–7.35); PZ0.001). A doubling
of androstenedione was significantly associated with an
increased risk of invasive serous tumors (1.67 (1.09–2.55);
PZ0.02) and a decreased risk of endometrioid tumors
(0.33 (0.15–0.73); PZ0.006), after adjusting for testo-
sterone. After adjustment for androgens, a doubling of
17-OHP was no longer significantly associated with the
risk of borderline serous tumors (from 46 to 23% increased
risk for 17-OHP).
There was no evidence of heterogeneity (phetO0.05)
by age at blood donation (histology-specific; below/above
median) or years between blood donation and diagnosis
(histology-specific; below/above median), number of
children, or study cohort. Heterogeneity by age at
diagnosis (!51 vs R51 years, aproxy for menopausal
status at diagnosis; Table 4) was observed in endometrioid
tumors for a doubling of E2 concentrations (!51 years:
1.36 (0.84–2.22) and R51 years: 14.11 (2.14–93.00);
PhetZ0.02), but as only 14 cases were diagnosed at or
after the age of 51 years, this result should be regarded
with caution. Although heterogeneity was not observed
for invasive or invasive mucinous tumors, associationshttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britainwith androgens in women diagnosed at the age of
!51 years were stronger than in older women. Hetero-
geneity by tumor stage at diagnosis (Table 5) was observed
in invasive serous tumors for a doubling of circulating
testosterone (localized: 1.91 (1.02–3.57) and advanced:
0.88 (0.68–1.14); PhetZ0.03) and SHBG concentra-
tions (localized: 2.38 (1.00–5.65) and advanced: 0.88
(0.61–1.27); PhetZ0.04), but not for any other hormones
or EOC subtypes.
Limiting the analyses of androgens to women with
information on gestational age at blood sampling did not
change risk estimates with the exception of a doubling
of androstenedione which was significantly associated
with an increased risk of borderline serous tumors (1.50
(1.10–2.05); PZ0.01). Limiting the analysis to women
with lag-time O2 or O3 years, or who provided a blood
sample during a full-term pregnancy, did not change
the risk estimates. The results did not materially change
when only women who donated blood during the last
pregnancy before diagnosis or selection as a control
were included. Analyses limited to members of the FMC
yielded similar results and analyses restricted to the
NSMC (nZ109 cases) were in the same direction but
non-significant due to the lack of power.Discussion
This is the first prospective case-control study, to our
knowledge, examining sex steroid concentrations during
pregnancy and the subsequent risk of EOC. We observed
heterogeneity in the associations between sex steroid
hormones with respect to EOC subtypes: higher androgen
concentrations were associated with an increased risk of
borderline serous and mucinous tumors, whereas higher
E2 was positively associated with the risk of endometrioid
tumors. None of the studied hormones were associated
with the risk of invasive serous tumors or clear cell tumors.
Progesterone and SHBG were not associated with the risk
of EOC, regardless of tumor histology and invasiveness.
There are substantial alterations in the secretion,
metabolism, and concentrations of circulating hormones
in maternal serum during gestation. First and early second
trimester androgen concentrations are similar to those in
non-pregnant women, with maternal testosterone concen-
tration increasing gradually throughout pregnancy and
androstenedione concentrations remaining relatively stable
(O’Leary et al. 1991, Taylor & Lebovic 2004). During the very
first weeks of pregnancy, the corpus luteum secretes
progesterone, 17-OHP, and E2 in increasing quantities.
The major site of synthesis for progesterone and E2 shiftsPublished by Bioscientifica Ltd.
Table 4 ORs (95% CI) for doubling of circulating hormone concentrations by age at diagnosis from the Finnish Maternity Cohort
(1983–2009) and the Northern Sweden Maternity Cohort (1975–2011)a
Age at diagnosis !51 years Age at diagnosis R51 years
PhetCa/Co OR (95% CI) Ca/Co OR (95% CI)
Invasive tumors
Testosterone 475/1228 1.32 (1.12–1.55) 165/381 1.05 (0.81–1.36) 0.15
Androstenedione 475/1227 1.40 (1.18–1.65) 165/382 1.10 (0.84–1.43) 0.13
17-OHP 357/1004 1.26 (1.04–1.53) 94/247 0.98 (0.66–1.45) 0.26
Progesterone 357/1005 1.14 (0.88–1.48) 94/247 1.04 (0.62–1.75) 0.76
Estradiol 357/1005 1.07 (0.91–1.27) 94/247 1.23 (0.88–1.72) 0.47
SHBG 350/993 1.04 (0.85–1.27) 79/216 1.07 (0.73–1.58) 0.88
Invasive serous tumors
Testosterone 195/506 1.01 (0.78–1.31) 87/207 1.04 (0.72–1.53) 0.88
Androstenedione 195/506 1.23 (0.94–1.61) 87/208 1.10 (0.77–1.57) 0.63
17-OHP 145/413 1.27 (0.93–1.73) 53/142 0.91 (0.55–1.51) 0.27
Progesterone 145/413 1.25 (0.82–1.88) 53/142 1.01 (0.53–1.92) 0.59
Estradiol 145/413 0.91 (0.69–1.21) 53/142 0.95 (0.64–1.42) 0.86
SHBG 142/407 0.98 (0.71–1.35) 43/121 0.98 (0.53–1.78) 0.98
Invasive mucinous tumors
Testosterone 128/339 1.46 (1.07–1.99) 22/49 0.94 (0.52–1.68) 0.19
Androstenedione 128/338 1.64 (1.18–2.28) 22/49 1.05 (0.55–2.02) 0.23
17-OHP 103/291 1.29 (0.90–1.84) 11/30 1.33 (0.49–3.64) 0.95
Progesterone 103/292 1.38 (0.82–2.31) 11/30 1.19 (0.24–5.78) 0.86
Estradiol 103/292 1.18 (0.87–1.59) 11/30 2.07 (0.47–9.16) 0.46
SHBG 102/290 1.10 (0.72–1.67) 11/29 1.11 (0.56–2.21) 0.97
Endometrioid tumors
Testosterone 67/159 1.47 (0.95–2.27) 34/76 1.20 (0.62–2.32) 0.61
Androstenedione 67/159 1.06 (0.69–1.64) 34/76 0.92 (0.45–1.90) 0.74
17-OHP 41/111 0.87 (0.49–1.56) 19/48 1.00 (0.36–2.76) 0.82
Progesterone 41/111 0.86 (0.39–1.88) 19/48 1.17 (0.30–4.52) 0.69
Estradiol 41/111 1.36 (0.84–2.22) 19/48 14.11 (2.14–93.00) 0.02
SHBG 39/108 0.92 (0.49–1.73) 16/42 1.84 (0.61–5.56) 0.28
17-OHP, 17-hydroxyprogesterone; Ca, number of cases; Co, number of controls; OR, odds ratio; Phet, test for heterogeneity; SHBG, sex hormone-binding
globulin.
aAdjusted for gestational age (except for testosterone and androstenedione).
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(after the fifth week of gestation), and concentrations of
these hormones increase further, whereas the concentra-
tion of 17-OHP decreases (Taylor & Lebovic 2004).
Support for an involvement of androgens in the
pathogenesis of EOC comes from results of in vitro studies
demonstrating increased cell proliferation of normal
ovarian surface epithelial cells after androgen adminis-
tration (Syed et al. 2001, Edmondson et al. 2002) and
epidemiological studies showing a protective effect of
OC use (which reduces circulating androgen levels and
ovarian androgen synthesis (Lukanova & Kaaks 2005))
(Wiegratz et al. 1995). Women diagnosed with poly-
cystic ovary syndrome, a hyper-androgenic disorder,
might be at increased risk but available data are sparse
and inconclusive (Schildkraut et al. 1996, Olsen et al.
2008, Bodmer et al. 2011).
However, results from the three largest prospective
studies on androgens reported thus far (Rinaldi et al. 2007,http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great BritainTworoger et al. 2008) did not show any association with
the risk or report any inverse association of andro-
stenedione for invasive serous tumors (Ose et al. 2014).
In the current study, we observed an increased risk with
both studied androgens for borderline serous tumors
and mucinous tumors. Our study differs from previous
investigations of the association between androgens and
EOC in two important ways. First, this study is the first, to
our knowledge, with the statistical power to study the risk
associations with respect to tumor invasiveness and
histology. Most of the previous reports included mainly
invasive serous tumors, with negligible numbers of
borderline and mucinous tumors. In the current study,
we were able to investigate associations with the rarer
subtypes, which are usually observed at a younger age
(Chen et al. 2003). Secondly, blood samples used in our
study were collected exclusively from pregnant women
(by definition premenopausal); androgen concentrations
are higher in premenopausal women when compared withPublished by Bioscientifica Ltd.
Table 5 ORs (95% CI) for doubling of circulating hormone concentrations in invasive tumors by tumor stage from the Finnish
Maternity Cohort (1983–2009)a
Local (stage I) Advanced (stages II–IV)
PhetCa/Co OR (95% CI) Ca/Co OR (95% CI)
Invasive tumors
Testosterone 150/377 1.44 (1.10–1.90) 331/804 1.11 (0.91–1.34) 0.12
Androstenedione 150/377 1.44 (1.09–1.90) 331/805 1.17 (0.96–1.43) 0.24
17-OHP 104/292 1.15 (0.82–1.61) 213/580 1.24 (0.95–1.61) 0.74
Progesterone 104/292 1.18 (0.70–1.98) 213/580 1.27 (0.90–1.81) 0.81
Estradiol 104/292 1.19 (0.87–1.61) 213/580 1.09 (0.87–1.36) 0.66
SHBG 100/284 1.37 (0.90–2.08) 199/563 1.06 (0.79–1.42) 0.32
Invasive serous tumors
Testosterone 38/96 1.91 (1.02–3.57) 196/481 0.88 (0.68–1.14) 0.03
Androstenedione 38/96 1.60 (0.91–2.80) 196/482 1.09 (0.84–1.40) 0.22
17-OHP 23/67 1.37 (0.75–2.51) 131/360 1.28 (0.90–1.81) 0.84
Progesterone 23/67 1.44 (0.60–3.41) 131/360 1.33 (0.84–2.09) 0.88
Estradiol 23/67 1.41 (0.75–2.67) 131/360 0.89 (0.67–1.18) 0.20
SHBG 23/67 2.38 (1.00–5.65) 120/341 0.88 (0.61–1.27) 0.04
Invasive mucinous tumors
Testosterone 78/198 1.31 (0.90–1.90) 32/83 1.46 (0.78–2.71) 0.77
Androstenedione 78/198 1.45 (0.98–2.13) 32/83 1.79 (0.91–3.53) 0.59
17-OHP 57/161 1.15 (0.72–1.84) 22/63 1.93 (0.92–4.04) 0.24
Progesterone 57/161 1.73 (0.79–3.81) 22/63 2.96 (0.93–9.43) 0.45
Estradiol 57/161 1.23 (0.82–1.86) 22/63 1.42 (0.65–3.09) 0.75
SHBG 56/160 1.40 (0.77–2.55) 22/63 1.41 (0.51–3.89) 0.98
Endometrioid tumors
Testosterone 18/45 1.12 (0.49–2.56) 62/139 1.53 (0.97–2.42) 0.52
Androstenedione 18/45 1.05 (0.45–2.46) 62/139 1.05 (0.66–1.65) 0.99
17-OHP 13/35 0.87 (0.32–2.34) 33/85 0.75 (0.38–1.48) 0.82
Progesterone 13/35 0.43 (0.07–2.72) 33/85 0.86 (0.37–2.04) 0.51
Estradiol 13/35 0.71 (0.27–1.86) 33/85 2.15 (1.06–4.36) 0.07
SHBG 11/30 0.65 (0.20–2.07) 31/85 1.39 (0.67–2.85) 0.28
17-OHP, 17-hydroxyprogesterone; Ca, number of cases; Co, number of controls; OR, odds ratio; Phet, test for heterogeneity; SHBG, sex hormone-binding
globulin.
aAdjusted for gestational age (except for testosterone and androstenedione).
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only 20% (Ose et al. 2014) to 42% (Helzlsouer et al. 1995)
of cases were premenopausal.
It has been proposed that EOC originates via two main
pathways of carcinogenesis and can be divided into two
subtypes (type I and type II tumors; Kurman & Shih 2011,
Lim & Oliva 2013). Type I tumors include low-grade
serous and endometrioid carcinoma, clear cell, mucinous,
and malignant Brenner tumors that develop slowly and
are often diagnosed at an early stage. These tumors are
typically confined to one ovary and progress from benign,
with increasing degrees of atypia, to non-invasive and
then invasive tumors. Thus, borderline ovarian tumors
might be the precursors of type I tumors.
Type II tumors include high-grade serous and endo-
metrioid carcinoma, undifferentiated, malignant mixed
mesodermal, and transitional cell tumors that are highly
aggressive and usually present at an advanced stage. It has
been suggested that type II tumors mainly originate fromhttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britainthe epithelium outside the ovary and invade the ovary
secondarily (Kurman & Shih 2011, Lim & Oliva 2013).
We observed significant positive associations between
androgen concentrations and borderline/invasive muci-
nous, as well as borderline serous subtypes, indicating
that androgens may be involved in the development of the
slowly growing tumors in the ovaries, whereas they do not
appear to influence the risk of the most aggressive cancers,
which are probably of extraovarian origin. This hypothesis
is also supported by the observation in our study that risk
increases for a doubling of testosterone concentrations
in invasive serous tumors diagnosed as localized (proxy for
type I: 1.91 (1.02–3.57)), but not advanced disease (proxy
for type II: 0.88 (0.68–1.14); PhetZ0.03).
Results from experimental studies and a number of
indirect observations indicate that elevated progesterone
concentrations may be inversely associated with the
risk of EOC. Progesterone has been shown to have
a potent apoptotic effect on the surface epitheliumPublished by Bioscientifica Ltd.
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ovarian cancer cells through FOXO1 (Diep et al. 2013).
Results from epidemiological studies consistently indicate
an inverse association of full-term pregnancies, increasing
parity, and the use of OCs with EOC (Tsilidis et al. 2011,
Merritt et al. 2013). Owing to its potent apoptotic effect
and elevated production during pregnancy, progesterone
is the most plausible candidate to mediate a ‘washout
effect’, i.e., elimination from the ovary of cells that have
undergone malignant transformation, a hypothesis pro-
posed to explain the greater protective effect of pregnan-
cies completed at an older age (Adami et al. 1994). In
addition, results from observational studies have indicated
that incomplete pregnancies confer less protection than a
pregnancy conducted to term (Whittemore et al. 1992,
Riman et al. 2002) or are not associated with the risk (Risch
et al. 1994).
However, we observed no association between early
pregnancy progesterone and the risk of EOC. One
explanation for the lack of association could be that only
the very high progesterone concentrations as observed
during the third trimester are etiologically important,
whereas the substantially lower hormone concentrations
during the first trimester are not. Results obtained using
cell culture models indicate that growth inhibition and
apoptosis occur only atveryhighconcentrations (R10K6 M;
Edmondson et al. 2002). In addition, during multiple
pregnancies, progesterone concentrations are higher
compared with singleton pregnancies and women with a
history of multiple births are at a reduced risk to develop
non-mucinous EOC (Whiteman et al. 2000).
Our finding of a positive association between estrogen
concentrations with the risk of endometrioid tumors
is novel. During pregnancy, E2 is synthesized by aro-
matization of androgens, mainly in the placenta, with
androgens derived from the ovary, the maternal adrenal,
and also de novo synthesis in placental syncytio-
trophoblasts (Escobar et al. 2011). Elevated estrogen
concentrations are consistently associated with an
increased risk of endometrial cancer in postmenopausal
women (Lukanova et al. 2004, Allen et al. 2008). Further-
more, endometrial cancer and EOC share similar risk
factor profiles, as well as several common genes and
pathways that are involved in their molecular pathogenesis
(Merritt & Cramer 2010). It has also been reported that
patients with endometriosis, which is associated with
molecular aberrations that favor increased local pro-
duction of E2 (Worley et al. 2013), are at an increased
risk of developing endometrioid EOC (Pearce et al. 2012).
Although clear cell tumors may originate in part fromhttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-14-0282 Printed in Great Britainendometriosis, we did not find any association between
E2 and clear cell tumors. This finding might be due to the
small number of cases in our study (nZ26), but it is
consistent with the hypothesis that clear cell tumors may
arise from endometriosis through mechanisms indepen-
dent of hormonal signaling (Conklin & Gilks 2013).
Our study has a number of strengths. We have
presented data from two unique Maternity Cohorts in
Finland and Northern Sweden and have conducted the
largest prospective study on pre-diagnostic sex steroids
and EOC to date (1052 vs 565 cases in the largest previous
study by Ose et al. (2014)) with detailed analyses by tumor
histology. As this study was conducted in a pregnant
population, it was easier to measure the progesterone
levels, because early pregnancy concentrations do not
cycle as observed in non-pregnant premenopausal
women. As the population was relatively young (median
age at blood drawZ31.5 years), we had sufficient statistical
power to assess invasive and borderline tumors. Case and
control subjects were tightly matched for age and date
at sampling, as well as parity at the index pregnancy, thus
controlling for several sources of potential confounding
factors (e.g. hormone concentrations differing by parity).
A major limitation of this study is the lack of
information on grade and the incomplete data on stage
(available for 824 (78%) cases). However, analyses by stage
for invasive serous tumors showed the expected hetero-
geneity. Another limitation is the lack of data on OC use
before pregnancy. However, former OC use is unlikely to
influence hormone concentrations during pregnancy as
steroid levels suppressed during OC use return to normal
levels within one cycle after cessation (Mall-Haefeli et al.
1983). Although study samples had been stored for a long
time (median 21 years) at relatively high temperatures
(K25/K20 8C), hormone levels were uncorrelated with
time in storage, as has been reported previously (Holl et al.
2008), and case and control samples were stored under
the same conditions. Another limitation is that we carried
out multiple statistical tests to analyze associations with
histological subtypes and thus some of our findings could
be due to chance.
In summary, we provide evidence that associations
of steroids and the risk of EOC vary with respect to tumor
histology and invasiveness as we observed i) positive
associations of androgens with borderline serous, invasive,
and borderline mucinous tumors; ii) positive associations
of E2 with endometrioid, and to a lesser extent with
borderline tumors; and iii) no associations with invasive
serous tumors. These results support a role of sex steroid
hormones in the etiology of EOC arising in the ovaries, butPublished by Bioscientifica Ltd.
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invasive serous tumors, which are presumed to originate
in the fallopian tubes and metastasize to the ovaries.
Our findings provide additional evidence that EOC is a
heterogeneous disease and indicate that further research
on sex steroids and the rarer histological subtypes
(endometrioid, clear cell, and mucinous) are necessary.Supplementary data
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